Tyra Biosciences, Inc.
General ticker "TYRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $718.1M (TTM average)
Tyra Biosciences, Inc. follows the US Stock Market performance with the rate: 41.0%.
Estimated limits based on current volatility of 3.7%: low 20.71$, high 22.29$
Factors to consider:
- Total employees count: 49 (+28.9%) as of 2023
- Top business risk factors: Operational and conduct risks, Significant losses, Pandemic risks, Regulatory and compliance, Market competition
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.99$, 20.59$]
- 2025-12-31 to 2026-12-31 estimated range: [7.61$, 17.78$]
Financial Metrics affecting the TYRA estimates:
- Negative: with PPE of -9.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.58 <= 0.33
- Positive: Shareholder equity ratio, % of 94.39 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -12.10
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TYRA quotes
Long-term TYRA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $58.93MM | $79.94MM | $104.18MM |
| Operating Income | $-58.93MM | $-79.94MM | $-104.18MM |
| Non-Operating Income | $3.60MM | $10.81MM | $17.70MM |
| R&D Expense | $43.01MM | $62.52MM | $80.08MM |
| Income(Loss) | $-55.33MM | $-69.13MM | $-86.48MM |
| Profit(Loss)* | $-55.33MM | $-69.13MM | $-86.48MM |
| Stockholders Equity | $257.83MM | $204.26MM | $343.15MM |
| Assets | $266.18MM | $225.86MM | $363.56MM |
| Operating Cash Flow | $-50.28MM | $-50.14MM | $-69.77MM |
| Capital expenditure | $0.56MM | $0.77MM | $0.66MM |
| Investing Cash Flow | $-0.56MM | $-144.60MM | $-98.40MM |
| Financing Cash Flow | $0.63MM | $1.54MM | $202.14MM |
| Earnings Per Share** | $-1.32 | $-1.62 | $-1.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.